IDIOPATHIC CD4 LYMPHOPENIA
Clinical trials for IDIOPATHIC CD4 LYMPHOPENIA explained in plain language.
Never miss a new study
Get alerted when new IDIOPATHIC CD4 LYMPHOPENIA trials appear
Sign up with your email to follow new studies for IDIOPATHIC CD4 LYMPHOPENIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug trial aims to help rare immune disorder
Disease control Recruiting nowThis early-stage study tests whether belimumab is safe for people with idiopathic CD4 lymphopenia (ICL), a rare condition causing low CD4 white blood cells and increased infection risk. About 20 adults aged 18-70 with ICL and autoantibodies will receive 8 doses of belimumab intra…
Matched conditions: IDIOPATHIC CD4 LYMPHOPENIA
Phase: PHASE1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
Experimental drug aims to rebuild immune defenses in rare disorder
Disease control Recruiting nowThis study tests an experimental drug called NT-I7 in people with idiopathic CD4 lymphopenia (ICL), a condition where low CD4 immune cells lead to severe infections and other diseases. The goal is to see if NT-I7 can safely increase CD4 cell counts. About 60 adults aged 18–75 wil…
Matched conditions: IDIOPATHIC CD4 LYMPHOPENIA
Phase: PHASE1, PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC